Proteins and Peptides

06 Jan 2021 Inhibrx Announces Phase 1 Dose Escalation Results of INBRX-106, a Novel Hexavalent OX40 Agonist
06 Jan 2021 AsclepiX Therapeutics, Inc. Doses First Patient in Phase 1/2a Trial of AXT107 Intravitreal Self-Forming Gel Depot Peptide for Diabetic Macular Edema (DME)
05 Jan 2021 Inozyme Pharma Announces Authorization to Proceed in U.S. and U.K. with Phase 1/2 Clinical Trial of INZ-701 for the Treatment of ENPP1 Deficiency
05 Jan 2021 Pandion Therapeutics Announces Positive Top-Line Phase 1a Clinical Data Showing PT101 was Well-Tolerated and Selectively Expanded Regulatory T cells
05 Jan 2021 US FDA Accepts Regulatory Submission from Pfizer and OPKO for Review of Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency
30 Dec 2020 Codiak Reports Positive Initial Phase 1 Results for exoIL-12™ Demonstrating Tolerability and Absence of Systemic IL-12 Exposure in Healthy Volunteers
29 Dec 2020 Clovis Oncology Submits Investigational New Drug Applications for Novel Peptide-Targeted Radionuclide FAP-2286 for Therapeutic and Imaging Clinical Trial
29 Dec 2020 Novo Nordisk files for EU regulatory approval of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes
23 Dec 2020 Jazz Pharmaceuticals Announces Initiation of Biologics License Application Submission for JZP-458 for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
23 Dec 2020 ABIONYX Initiates a Phase 2a Clinical Trial With CER-001 in Septic Patients at High Risk of Developing Acute Kidney Injury
22 Dec 2020 ImmunityBio Announces Primary Endpoint Met of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 72% Complete Response Rate
22 Dec 2020 The European Commission Grants Marketing Authorization for PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Relapsing-Remitting Multiple Sclerosis
18 Dec 2020 Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-413 in Patients with Hearing Loss
18 Dec 2020 Nanoform and Herantis partner to look for opportunities to enhance BBB penetration of CDNF and xCDNF molecules
18 Dec 2020 Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
18 Dec 2020 Novo Nordisk files for EU regulatory approval of once-weekly semaglutide 2.4 mg for weight management
17 Dec 2020 Molecular Partners Announces New Clinical Data, Immunomodulation Platform Advances, and Virology Portfolio Strategy
16 Dec 2020 Arecor Limited: First Patient Dosed in Phase I Clinical Trial of Ultra-Concentrated Rapid Acting Insulin Candidate, AT278, for Diabetes
16 Dec 2020 Novo Nordisk to enter phase 3 development in Alzheimer’s disease with oral semaglutide
16 Dec 2020 Nektar Therapeutics Announces Dosing of First Patients in Phase 1/2 Study of its IL-15 Agonist, NKTR-255, in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma or Colorectal Cancer
11 Dec 2020 Xeris Pharmaceuticals Receives Positive CHMP Opinion for Ogluo™, Its Ready-To-Use (RTU) Glucagon for Injection, for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus
10 Dec 2020 Neoleukin Therapeutics Announces Submission of Investigational New Drug Application for NL-201 De Novo Protein Immunotherapy Candidate for Cancer
09 Dec 2020 Lilly's tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes
08 Dec 2020 Altimmune Commences Dosing in Phase 1 Clinical Trial of ALT-801, a Long-Acting GLP-1/Glucagon Receptor Dual Agonist for the Treatment of NASH
08 Dec 2020 Nektar Therapeutics Announces Presentation of Preclinical Data for NKTR-255, its Novel IL-15 Agonist, at the American Society of Hematology (ASH) 2020 Annual Meeting

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top